輸入代號或公司名稱後按 Enter
HRMY

Harmony Biosciences Holdings, Inc.

+0.24 (+0.57%)前一交易日收盤 2026-09-17
美股 · Nasdaq · 製藥生技 · 製藥SIC 2834
42.45USD198K成交股數2.5B市值13.8本益比(近四季)2.6股價營收比+30.3%營收年增(近四季)2026-11-03下次財報

財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束

逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。

營收與利潤率近 16 季

稀釋 EPS近 16 季 · 美元

現金流近 16 季

股東回饋近 16 季 · 庫藏股與股利

損益表 逐季 · 最新在左 · 小字是年增率

科目26Q226Q125Q325Q225Q124Q424Q324Q224Q123Q323Q223Q1
營收261M+41%215M+7%239M+29%200M+16%185M+19%201M+26%186M+39%173M+45%155M160M134M119M
營業成本63.2M44.5M59.7M38.2M32.0M54.4M42.8M32.1M27.5M32.3M25.0M20.8M
毛利198M+30%171M+16%180M+26%162M+15%153M+20%147M+15%143M+31%141M+43%127M128M109M98.3M
毛利率75.8%79.3%75.1%81.0%82.7%73.0%77.0%81.4%82.2%79.8%81.4%82.6%
研發費用46.6M69.4M55.0M50.2M34.5M34.7M25.4M63.6M22.2M17.5M15.0M13.3M
銷售管理費用28.1M32.5M29.8M33.9M31.2M28.9M28.6M27.2M25.7M22.5M22.8M22.1M
營業利益89.3M+59%37.3M-33%65.5M+6%48.2M+126%56.2M+8%55.7M-14%61.7M+32%21.4M-47%52.0M64.5M46.9M40.4M
營業利益率34.2%17.3%27.3%24.0%30.4%27.7%33.2%12.4%33.7%40.3%34.9%33.9%
稅後淨利75.4M+66%32.5M-34%50.9M+10%39.8M+243%45.6M+19%49.5M+29%46.1M+34%11.6M-61%38.3M38.5M34.3M29.5M
淨利率28.9%15.1%21.2%19.8%24.7%24.6%24.8%6.7%24.8%24.0%25.6%24.8%
稀釋 EPS1.28+64%0.55-35%0.87+10%0.68+240%0.78+16%0.85+35%0.79+41%0.20-58%0.670.630.560.48
稀釋股數58.8M58.8M58.7M58.4M58.5M57.9M58.1M57.5M57.6M60.7M60.7M61.2M

資產負債表 期末餘額

科目26Q226Q125Q325Q225Q124Q424Q324Q224Q123Q323Q223Q1
現金與約當現金550M589M647M546M489M453M387M317M333M325M317M288M
應收帳款111M108M101M93.0M106M83.0M81.5M83.2M79.7M67.3M63.8M52.6M
存貨6.4M5.3M6.9M6.1M6.4M7.2M6.9M5.6M5.9M5.1M4.9M4.1M
總資產1.4B1.3B1.2B1.1B1.1B999M928M858M847M778M760M715M
有息負債134M139M149M153M158M163M168M171M175M182M180M185M
總負債374M361M373M335M335M340M331M320M332M296M275M272M
股東權益999M910M835M773M721M659M597M539M515M481M485M443M
負債比27.2%28.4%30.9%30.2%31.7%34.0%35.7%37.3%39.1%38.1%36.2%38.0%
淨現金(現金 − 有息負債)416M451M498M393M331M290M220M146M158M142M137M103M

現金流量表 單季

科目26Q226Q125Q325Q225Q124Q424Q324Q224Q123Q323Q223Q1
營業現金流27.8M34.0M+9%31.1M42.6M
資本支出128K5K
自由現金流33.9M+9%31.1M
折舊攤銷
買回庫藏股
現金股利
自由現金流率18.3%20.1%

營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度

業務分部2025 年度 · 868M
Rare Neurological Diseases868M100.0%+21.5%

各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。

年度 10-K

財年營收年增稅後淨利淨利率稀釋 EPS自由現金流
FY2025868M+21.5%159M18.3%2.71348M
FY2024715M+22.8%145M20.4%2.51219M
FY2023582M+32.9%129M22.1%2.13219M
FY2022438M+43.4%181M41.4%2.97144M
FY2021305M+91.2%34.6M11.3%0.5898.3M
FY2020160M+2564.6%−36.9M-23.1%-2.48−3.0M
FY20196.0M−152M-2,535.1%-24.07−75.6M